Literature DB >> 12126216

Topiramate and weight loss in patients with neurodevelopmental disabilities.

Rex O Brown1, Carla D Orr, Debra L Hanna, John E Williams, Roland N Dickerson.   

Abstract

STUDY
OBJECTIVE: To characterize weight changes in patients with neurodevelopmental disabilities who received topiramate.
DESIGN: Retrospective, observational study.
SETTING: State-supported developmental center. PATIENTS: Fifteen patients with neurodevelopmental disabilities who received topiramate therapy
MEASUREMENTS AND MAIN RESULTS: Monthly weights for 1 year after the start of topiramate therapy were recorded. Mean body weight at drug initiation differed significantly compared with the nadir weight during the next 12 months (52.2+/-7.5 vs 49.9+/-7.2 kg, p<0.02). Twelve patients who were receiving ad libitum oral diets demonstrated a significant decrease in body weight (52.1+/-7.5 vs 49.0+/-7.3 kg, p<0.01), whereas the three patients who received enteral nutrition through enterostomy did not experience significant weight loss.
CONCLUSION: Weight loss is common in patients with neurodevelopmental disabilities who receive topiramate. Since patients who received oral diets lost weight whereas those receiving enteral nutrition did not, decreased nutrient intake is the likely cause of weight loss.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126216     DOI: 10.1592/phco.22.11.831.33620

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  2 in total

1.  Zonisamide decreases ethanol intake in rats and mice.

Authors:  Clifford M Knapp; Melissa Mercado; Tara Lynn Markley; Steven Crosby; Domenic A Ciraulo; Conan Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

Review 2.  Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy.

Authors:  Victor Biton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.